Spectrum Antimicrobials, Inc. — SEC Form D Filing

Spectrum Antimicrobials, Inc. filed an SEC Form D on April 1, 2026, reporting $26.39M raised in Pharmaceuticals.

Form D filing details

Filing
SEC Form D
Filing date
April 1, 2026
Amount reported
$26.39M
Round stage
Seed
Industry
Pharmaceuticals
Website
https://spectrumantimicrobials.com/

What the company does

Securities: Equity. Exemption: Rule 506(c). Incorporated: NEVADA

Problem

Spectrum Antimicrobials addresses the critical issue of infections in healthcare settings, including surgical sites and wound care.

Solution

The company develops proprietary antiviral and antimicrobial products that prevent infections and promote healing without encouraging drug resistance.

Why now

The increasing prevalence of antibiotic-resistant infections and a heightened awareness of infection control in healthcare necessitate innovative solutions.

Verdict

Investors said yes because Spectrum Antimicrobials presented a timely solution to the rising threat of antibiotic resistance, not because they had a clearly defined budget owner or replacement cost. The implicit bet was on a healthcare paradigm shift toward innovative infection control, but the limited upside lies in the crowded space of antimicrobial solutions where differentiation is crucial yet fragile.

Source: SEC EDGAR Form D filing